These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31968243)

  • 1. Striatal Projection Neurons Require Huntingtin for Synaptic Connectivity and Survival.
    Burrus CJ; McKinstry SU; Kim N; Ozlu MI; Santoki AV; Fang FY; Ma A; Karadeniz YB; Worthington AK; Dragatsis I; Zeitlin S; Yin HH; Eroglu C
    Cell Rep; 2020 Jan; 30(3):642-657.e6. PubMed ID: 31968243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
    Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
    J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits.
    McKinstry SU; Karadeniz YB; Worthington AK; Hayrapetyan VY; Ozlu MI; Serafin-Molina K; Risher WC; Ustunkaya T; Dragatsis I; Zeitlin S; Yin HH; Eroglu C
    J Neurosci; 2014 Jul; 34(28):9455-72. PubMed ID: 25009276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
    Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
    J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic Huntington Alters BMP Signaling and Synaptic Growth through Local Disruptions of Endosomal Compartments.
    Akbergenova Y; Littleton JT
    J Neurosci; 2017 Mar; 37(12):3425-3439. PubMed ID: 28235896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin.
    Parsons MP; Kang R; Buren C; Dau A; Southwell AL; Doty CN; Sanders SS; Hayden MR; Raymond LA
    J Biol Chem; 2014 Feb; 289(6):3518-28. PubMed ID: 24347167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
    Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
    J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.
    Peng C; Zhu G; Liu X; Li H
    Neurosci Bull; 2018 Oct; 34(5):747-758. PubMed ID: 29713895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease.
    Pryor WM; Biagioli M; Shahani N; Swarnkar S; Huang WC; Page DT; MacDonald ME; Subramaniam S
    Sci Signal; 2014 Oct; 7(349):ra103. PubMed ID: 25351248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form.
    Yang H; Yang S; Jing L; Huang L; Chen L; Zhao X; Yang W; Pan Y; Yin P; Qin ZS; Tang B; Li S; Li XJ
    Nat Commun; 2020 May; 11(1):2582. PubMed ID: 32444599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.